Hematology Frontier

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort. This study, selected for oral presentation (O576), not only deepens our understanding of CNS involvement in DLBCL but also offers innovative perspectives for clinical management and treatment strategies. Hematology Frontier invited Dr. Xu to share insights into the significance of CSF-ctDNA testing, its potential role in future DLBCL clinical practice, and its far-reaching impact on patient treatment strategies.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis (O192). The findings revealed a novel connection between DNMT3A mutations and immune microenvironment dysregulation, offering a fresh perspective on the origins and progression of clonal hematopoiesis. Hematology Frontier invited Dr. Liang for an in-depth discussion on the clinical significance of this research and its potential future applications.

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions (P1676, P3113, P4442). Hematology Frontier invited Professor Huang to share their insights and the clinical implications of these studies directly from the ASH venue.

On December 17, 2024, French time, at the annual award ceremony of the French National Academy of Medicine (ANM), Professor Weili Zhao form Shanghai Ruijin Hospital and Professor Anne Janin from Paris Diderot University jointly received the "Charpak-Dubousset Prize." The prize was personally presented by Christian Boitard, the Secretary-General of the Académie Nationale de Médecine, and Jacques Belghiti, the Deputy Secretary-General of the same institution, in recognition of their significant contributions to the field of lymphoma.

The 66th Annual Meeting of the American Society of Hematology (ASH) was held from December 7–10, 2024, in San Diego, USA. This prestigious gathering brought together global experts and scholars to discuss the latest advancements in hematology. At this year's conference, the Tianjin Medical University Cancer Institute and Hospital's lymphoma team presented 6 significant research studies. As part of the Hematology Frontier series, Dr. Huilai Zhang, the team leader, connected live from a domestic studio with her team on-site in the United States. Together, they delved into their findings, shared insights, and exchanged perspectives, bridging international and domestic expertise. Below is a detailed summary of their discussions, aimed at providing valuable guidance for clinical practice.

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024. As one of the most influential platforms for scientific communication in hematology, this global event attracted over 25,000 professionals, including clinicians, researchers, and healthcare leaders from more than 100 countries. The conference covered all aspects of malignant and non-malignant hematology, from cutting-edge research to clinical practice and therapeutic innovation, reflecting the latest advancements and future trends in the field.

The 66th American Society of Hematology Annual Meeting (ASH) was grandly held in San Diego, USA, from December 7th to 10th, 2024. This annual event is one of the most influential scientific communication platforms in the field of hematology worldwide. This edition of the ASH Annual Meeting attracted over 25,000 professionals, including clinicians, scientists, researchers, and healthcare decision-makers from more than 100 countries around the globe. The conference covered all aspects of malignant and non-malignant hematology, from basic scientific research to clinical practice, from drug development to therapeutic innovation, reflecting the latest advancements and future trends in the field of hematology.

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the fields of cell therapy and immune therapy from around the world. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Ibrahim Yakoub-Agha from the Lille University , France, to reveal the unlimited potential and broad prospects of cellular immunotherapy in myelofibrosis.

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. "Hematology Frontier" specially invited the conference chair and the chairman of the Asian Cellular Therapy Organization (ACTO), Dr. Akihiro Shimosaka, to share his profound insights on immune cell therapy, regenerative medicine, gene therapy, and the application of exosomes.

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Leo Luznik from Baylor College of Medicine,USA to share the latest progress of Bone Marrow Infiltrating T Cells (MITs) in the treatment of relapse after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). He revealed the potential and challenges of MITs in treating relapse after HSCT and looked forward to the future development direction of the field.